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Abstract
Subunit vaccines are playing a critical role in controlling numerous diseases and attract-
ing more and more research interests due to their numerous advantages over conven-
tional whole microbe-based vaccines. However, subunit vaccines are weak immunogens 
and thus have limited capacity in eliciting the humoral and cellular immunity against 
pathogens. Recently, nanoparticles (NPs) formed with certain small molecules through 
self-assembly have been employed as an effective carrier for subunit vaccines to play 
roles of adjuvant, delivery and stabilization of antigens, thus engendering a vaccine 
adjuvant-delivery system (VADS), which shows promises to overcome the hurdles in 
developing subunit vaccines. In particular, the small molecule-self-assembled NPs as 
a VADS can not only deliver vaccine ingredients to immune cells but also influence 
the immunoresponse toward a Th1 (type 1 T helper cell) and Th2 balanced pathway to 
establish both humoral and cellular immunity. This chapter describes the innovative 
VADSs based on the small molecule-self-assembled NPs, such as metal NPs (mNPs), 
emulsions, liposomes, and ISCOMs, which are elaborately designed for the develop-
ment of subunit vaccines.
Keywords: nanoparticle, self-assembly, immune response, mucosal vaccination, 
cellular immunity, nanocarrier, inorganic particle, danger-associated molecular pattern, 
targeted delivery
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1. Introduction
Modern vaccine development began from the use of vaccinia against smallpox by British 
physician Edward Jenner in the late eighteenth century and ever since has brought many 
products that have saved countless human lives from being claimed by numerous infectious 
pathogens, such as smallpox, measles, and rabies [1]. However, many pathogens such as 
human immunodeficiency virus (HIV), herpes simplex virus (HSV), and Ebola virus (EBV), 
still lack vaccines and are still posing a great threat to human health and life [2].
Vaccines are developed based on the antigenic components, which can stimulate the host 
immune system to set up immunity able to clear the abnormalities and usually include three 
types: the live attenuated whole microbe vaccines, the killed whole microbe vaccines, and 
the antigenic component-based subunit vaccines [3]. The former two types are regarded as 
the conventional vaccines with a high capacity of defending against deleterious organisms 
but, unfortunately, are also linked to a relatively poor safety profile due to their possible 
reversion of virulence and induction of deviated immunoresponses leading to unprotective 
and even harmful immunity and unacceptable inflammation. In contrast, the subunit vac-
cine is elaborately formulated with defined components including antigen (Ags) to induce 
immunoresponses which is accurately targeting the matched objects, thus causing few safety 
concerns and can be employed to fight both infectious pathogens and detrimental neoplasms 
carrying the identical Ags. Subunit vaccines since the notion emergence have attracted great 
research interests with numerous visible and all imaginable advantages [4], including high 
safety without reversion to virulent state; their production needing no dangerous microor-
ganisms; providing an alternative solution to the problematic culture for attenuating some 
pathogens; low risk of allergic or autoimmune reactions; customization to recognize certain 
pathogen-associated targets; feasible developing anticancer vaccine; carrying several peptide 
epitopes targeting different stages in the life cycle or subtypes of a pathogen; production in 
large scale in a pure state, in an economically and highly reproducible manner; high solubility 
allowing lyophilization to form stable dry products [4].
However, subunit vaccines often show a weak immune induction potency, due to lack of 
a large fraction of components associated with pathogen structural characteristics, which 
are broadly shared by pathogens but distinguishable from host molecules, collectively 
referred to as pathogen-associated molecular patterns (PAMPs) and able to activate the 
pattern recognition receptors (PRRs), such as the toll-like receptors (TLRs), the nucleotide-
binding oligomerization domain-like receptors (NOD-like receptors), retinoic-acid-induc-
ible gene-I-like receptors (RIG-I-like receptors), and C-type lectin receptors, to trigger as 
immunostimulators or an adjuvant mammalian innate immunoresponse sponsoring a series 
of adaptive reactions required for establishing the Ag-specific immunity [5]. Thus, while 
subunit vaccines are usually safer and less reactogenic than the whole organism vaccines, 
they often need an adjuvant or a vaccine adjuvant delivery system (VADS) to synergisti-
cally stimulate professional Ag-presenting cells (APCs) such as dendritic cells (DCs) and 
macrophages (MPs) for enhancing their immunization efficacy [6–10]. An adjuvant is a non-
specific immune-potentiating substance, which is capable of enhancing the body’s immune 
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response to the Ag or changes the type of immune response with some mechanisms that 
are not exactly known but are argued relevant to two fundamental aspects: (1) giving off 
dangerous signals by imposing damages on cells/tissues to activate the innate immune cells; 
(2) exciting PRRs of the innate immune cells, such as DCs, MPs, histiocytes and mast cells, 
to sponsor the subsequent adaptive responses [11, 12]. The available adjuvants are mainly 
micron- or nanometer-sized particles or aggregates which may be classified into two types: 
(1) the natural or synthetic substances with intrinsic adjuvanticity, such as alum (insoluble 
aluminum salt), squalene/squalane, saponin, chitosan, hyaluronic acid (HA), and various 
pattern recognition receptor agonists (PRRas); (2) functional carriers capable of playing roles 
of both adjuvant and delivery, thus regarded as vaccine adjuvant delivery system (VADSs), 
which are often formulated with nanoparticles (NPs) fabricated with various biocompatible 
materials, such as liposomes made of phospholipids and cholesterol, immune stimulating 
complexes (ISCOMs) of saponin and lipids, polymeric NPs made of PLGA or polystyrene, 
virus-like particles (VLPs) made of viral proteins, emulsions made of squalene and surfac-
tants, and the metal NPs (mNPs) made of aluminum or gold metal compounds, which prove 
an efficient VADSs able to enormously enhance vaccination efficacy [3, 13].
In this chapter, we describe design principles, main formulations and the state-of-the-art 
advances in developing novel VADSs constructed with different types of NPs, which are 
formed through small molecule self-assembly and herein, include liposomes, nondegradable 
inorganic metal NPs (mNPs), emulsions, ISCOMs. These small molecule-based NPs have 
been devised as a VADS with the potential to stimulate the Ag-specific humoral and cellular 
immune responses and are promising in preparation of next generation vaccines against a 
range of infectious pathogens.
2. VADS constructed with different types of NPs formed by  
self-assembly of small molecules
2.1. VADS constructed with metal nanoparticles (mNPs) formed by self-aggregation
Alum is the micron-sized aggregates of water-insoluble aluminum salts and is the first sub-
stance that was discovered able to boost the efficacy of vaccines and coined the term “vaccine 
adjuvant,” a concept which was put forward when scientists came to realize that certain materi-
als irrelevant to pathogens but able to enhance immunoresponse induced by vaccine [14]. Since 
1926, when first being used as an adjuvant, alum, such as aluminum phosphate, aluminum 
potassium sulfate, and aluminum hydroxide had been the only clinically used adjuvant in 
many subunit vaccines as well as the inactivated pathogen-based vaccines, until the approval of 
adjuvant calcium phosphate in diphtheria/pertussis (DT) vaccines [15]. Subsequently, an O/W 
nanoemulsions formed of squalene/Span 85/Tween 80, called MF59® was marketed as a VADS 
for delivering an influenza vaccine (Fluad®) in 1997, followed by AS04 (MPL/alum mixture) for 
delivering human papillomavirus (HPV, Cervarix®) and hepatitis B virus (HBV, Fendrix®) vac-
cines [16]. Alum forms a micron-sized VADS by just mixing the insoluble salt with other vac-
cine components or Ags and tends to function eliciting humoral over cellular immunity when 
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intramuscularly administered to humans. Though having successfully been used for nearly a 
century in human vaccines against numerous infectious diseases, such as hepatitis A and B, 
diphtheria-tetanus-pertussis (DTaP, Tdap), Haemophilus influenzae type b (Hib), HPV, and 
pneumococcus infection, alum is still argued to be associated with a potential risk for causing 
autoimmunity, long-term brain inflammation and neurological complications, as evidenced by 
the observation of severe disorders in recipients of alum-adjuvanted vaccines [17].
Thus, frustrated by the reactogenicity and the injury adverse effects associated alum while 
expected to enhance its capability to induce humoral and even cellular immunoresponses, 
researchers have for years endeavored to reshape the micron-sized salt adjuvant in mainly 
two ways: forging the micron-sized salt into NPs and coating surfaces with biocompatible 
materials. Recently, to develop an effective HIV vaccine, which is known a huge challenge 
almost since this virus discovery, Neutra’s group conjugated peptide epitopes derived from 
HIV-1 gp120 glycoprotein to the Al
2
O
3
 NPs with a size of about 350 nm, which showed able 
to stimulate the moderate antibody responses after intraperitoneal injection but failed to 
stimulate mucosal immunity [18]. Also, Cui’s group engineered 112 nm-sized aluminum 
hydroxide NPs and aluminum oxyhydroxide nanosticks with a length of 80 nm, long aspect 
ratio of 10 and low degree of crystallinity and showed that both aluminum NPs were able 
to facilitate in vitro APC uptake of the loaded protein Ags and induced in mice a stronger 
Ag-specific antibody response but milder local inflammation in the injection sites, compared 
with traditional aluminum microparticles [19, 20]. Furthermore, aluminum NPs proved able 
to stimulate in vitro APCs to produce uric acid, and, when injected into peritoneal cavity of 
mice, induced production of increased levels of uric acid, to contrast micron alum which did 
not in either case. The results suggest that aluminum has a stronger adjuvant activity in the 
form of NPs, as opposed to microparticles, may be partially attributed to their higher ability 
to induce endogenous danger signals such as uric acid [21].
Based on the phosphophilicity of aluminum, Wang and coworkers engineered the phospho-
lipid bilayer-coated aluminum nanoparticles (PLANs) formed via chemisorption between 
phospholipid and aluminum using a procedure of reverse ethanol injection-lyophilization 
(REIL) [7]. The researchers demonstrated that the anhydrous Ag-PLANs had a high stability 
satisfying the prerequisite requirements for distribution with the controlled temperature chain 
instead of the integrated cold chain [22] and that upon rehydration the Ag-carried PLANs 
could be instantly reconstituted to form an aqueous dispersion maintaining vaccine activ-
ity. Further exploration confirmed that the PLANs remarkably enhanced APC uptake of the 
delivered vaccines and when given subcutaneously to mice, induced more robust Ag-specific 
humoral as well as cellular immunoresponses, while stimulated less local inflammations, in 
comparison to microparticle alum, proving that the PLANs are an efficient VADS and possess 
numerous advantages over alum, which has been the widely used for clinical immunization 
for nearly a century [7].
In recent years, other types of NPs made of metal substances, such as calcium and gold, have 
also become a popular VADS, owing to their certain unique physicochemical properties 
including inertness with good biocompatibility, facile surface modification with functional 
molecules, and easy size and shape control. Chiu and coworkers coated the 25 nm-sized 
amorphous cores of calcium phosphate nanoparticles (CaP-NPs) with peptide Ags, thus 
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producing a particulate vaccine with a hydrodynamic size of 60 nm and found that the small 
core-shell assemblies induced in mice a 3-fold increase of anti-Ag titers 3 weeks post-injection, 
compared to a commercial aluminum phosphate adjuvant, suggesting that CaP-NPs may be 
an effective VADS delivery of vaccines [23]. Morcol et al. demonstrated that CaP-NPs were 
also a good VADS for the inactivated influenza A/CA/04/2009 (H1N1pdm) vaccine and could 
enormously boost production in the intramuscularly vaccinated mice of hemagglutina-
tion inhibition (HAI), virus neutralization (VN), and IgG antibody titers, at all dose levels, 
relative to the nonadjuvanted vaccine. In particular, the CaP-NP vaccine equally protected 
mice against influenza virus at 1/3 of the Ag dose of the nonadjuvanted or alum-adjuvanted 
vaccines, indicating that CaP-NPs are an promising VADS which may play a crucial role in 
production of a dose-sparing vaccine which is of a great importance during, in particularly, 
an influenza pandemic [24]. Also, Powell and coworkers constructed calcium carbonate NPs 
which had an average diameter of 200 nm and based on opposite charge attraction, coated 
with polylysine and polyglutamic acid and showed that this type of the CaCO
3
 NP-based 
VADS could efficiently facilitate maturation of DCs, which were simultaneously induced 
capable of cross-presentation of Ags. Notably, after a single injection in mice, CaCO
3
 NPs 
induced strong humoral and cellular immunity without triggering secretion of inflammatory 
cytokines, proving CaCO
3
 NPs are an efficient and safe VADS [25].
Gold nanoparticles (AuNPs) have unique physicochemical properties, such as an ultra-small 
size, large surface area to mass ratio, and high surface reactivity, presence of surface plasmon 
resonance (SPR) bands, biocompatibility and ease of surface functionalization, allowing this 
type of mNPs able to act as a versatile VADS bearing numerous beneficial features including, 
particularly, targeted delivery and stimulus-sensitive release. Chen et al. engineered gold NPs 
(AuNPs) with sizes ranging from 2 to 50 nm conjugated with foot-and-mouth disease virus 
associated peptide Ags and proved that gold NPs with a size of ranging in 2–17 nm induced 
strong humoral response, which was correlated to spleen uptake of gold NPs [26]. Gill’s group 
prepared gold NPs conjugated with M2e peptide, an extracellular domain of influenza A virus 
ion channel membrane matrix protein 2 (M2e) and demonstrated that intranasal administration 
to mice of AuNP-M2e plus soluble CpG induced lung B cell activation and robust serum anti-
M2e antibody response, resulting in high levels of both IgG1 and IgG2a subtypes [27]. Also, the 
group revealed that the antibodies generated by AuNP-M2e/CpG stimulation could bind to the 
homotetrameric form of M2 expressed on Madin-Darby canine kidney (MDCK) cells, which as 
an immunosorbent had been infected with H1N1, H3N2 or H5N1 strain of influenza viruses. 
Moreover, mice intranasally immunized with AuNP-M2e/CpG obtained 100, 92, and 100% 
protection against lethal challenges with A/California/04/2009 (H1N1pdm) pandemic strain, 
A/Victoria/3/75 (H3N2), and the highly pathogenic avian influenza virus A/Vietnam/1203/2004 
(H5N1), respectively, proving AuNP-M2e/CpG a promising VADS for developing a universal 
influenza vaccine, a desired Holy Grail for controlling the most prevalent infections [27].
2.2. VADS constructed with emulsions formed by self-assembly of surfactants
Emulsions are formed of two immiscible liquid phases, generally oil phase and water phase, 
with one phase organized into small droplets (inner phase), which, depending on composi-
tion and manufacturing process, have a size in a range of from tens of nanometers to several 
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microns, and are dispersed in a distinct continuous phase (outer phase) under stabilization 
by an interfacial surfactant layer. Emulsions, based on structural characteristics, are made of 
three classical types of single emulsions, double emulsions and Pickering emulsions: single 
emulsions include oil-in-water (O/W) type denoting oil droplets being emulsified in a bulk 
aqueous phase, and vice versa, the water-in-oil (W/O) type; double emulsions include O/W/O 
and W/O/W emulsions; and Pickering emulsions are a special type with an emulsifier of solid 
NPs replacing surfactants [28].
Notably, the emulsions formed of special oils, such as lanolin oil, cottonseed oil, and paraffin 
oil, were found, like alum, in some serendipitous way, of adjuvanticity in the early twentieth 
century and have ever since been widely used as a VADS to produce vaccines against patho-
gens. For example, lipovaccines used in the 1920s were in fact the formulations consisting of 
killed bacterial vaccines suspended in lanolin or cottonseed oils and proved able to induce 
immunoresponses with additional functions of dose spare and stability enhancement [29]. 
Freund adjuvants are the mostly known potent emulsion-based VADS including two types: 
incomplete Freund adjuvant(IFA), which is essentially a viscous crude W/O emulsion contain-
ing Ags in water phase using mineral paraffin as an oil phase and mannide monooleate as a 
surfactant; complete Freund adjuvant (CFA), which forms by addition to IFA of heat-killed 
mycobacteria (Mycobacterium tuberculosis) and has thus a high immunostimulating potency but 
also a high reactogenic toxicity, rendering the adjuvant to be used only in veterinary vaccines 
[30]. Though IFA is rather safe compared to CFA and was actually administered to hundreds of 
thousands of humans as an adjuvant in polio and influenza vaccines in the mid-twentieth cen-
tury, the severe local reactogenicity excluded the adjuvant from continuing clinical use [31].
Discarding the flaws of unacceptable toxicity and uncertain component associated with early 
emulsion adjuvants, modern emulsions as a VADS are usually formulated with well-defined 
factors, such as particle size, component and concentrations, and compatibility with antigens 
as well as human bodies, which are related to efficacy, safety, and stability [32]. Important 
lessons highlighted by early emulsion vaccines and deep insights into problems arising in use 
of the adjuvant inspired researchers to commit to developing an emulsion VADS with clear 
thoughts in several issues: (1) using biodegradable oil and the surfactants with an established 
safety profile in humans; (2) using the O/W instead of W/O emulsions to lower oil content 
for enhancing tolerability as well as the ease of use due to reduced viscosity; (3) enhancing 
potency with emulsions having a size <500 nm to promote APC uptake. As a result of the 
efforts directed toward these aspects, a breakthrough was made in the development of emul-
sion VADS in the 1980s when the squalene was explored as the oil phase of emulsions, which 
were thus rendered with an acceptable reactogenicity profile and potent adjuvant effects and 
were subsequently licensed as several proprietary products, including MF59 by Novartis, 
AS03® by GSK and AF03 by Sanofi Pasteur. MF59 is an O/W emulsion which is produced 
with a microfluidizer (MF) and contains squalene oil droplets stabilized by surfactants Tween 
80 and Span85 guaranteeing the size of 160 nm for sterilization by filtration and as a VADS has 
proven of potent immunogenicity and low reactogenicity for a range of Ags [16]. MF59 can 
induce robust immunoresponses through triggering vaccinated tissue-resident immune cells 
to secrete a number of chemokines, which recruit other immunocytes to amplify the chemokine 
gradient, resulting in a significant signal magnification and immune cell influx to establish 
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anti-Ag immunity. MF59 became the first emulsion-based VADS approved for delivering the 
seasonal influenza vaccine of Fluad® for human immunization in 1997 and followed by AS03, 
which is a 200 nm-sized O/W emulsion consisting of squalene/DL-a-tocopherol/Tween 80 and 
was approved for human use in GSK’s A/H1N1 pandemic flu vaccine Pandemrix® [33]; and 
then AF03, which is a 80 nm-sized O/W emulsion consisting of squalene/polyoxyethylene 
cetyl-stearyl ether/sorbitan oleate/mannitol and was approved for clinical immunization in 
Sanofi Pasteur’s pandemic influenza vaccine, Humenza® [34].
Now, novel types of emulsions are still actively formulated using various functional materials 
to constitute a VADS possessing desired properties, including high potent immunogenicity, 
targeting delivery of vaccines toward draining lymph nodes (dLNs) and APCs, enhanced 
cellular uptake, controlled release of Ags, rendering vaccine lysosome escape, and directing 
immunoresponses toward the Th1/Th2 type biased or balanced pathway [32]. Meanwhile, 
attempts in pushing into clinical trials of emulsion VADSs for delivery of cancer vaccines and 
other applications have also increasingly continued and are accompanied by endeavors in 
shedding light on the mechanisms involved in the action of emulsion adjuvants. Recently, 
Schmidt et al. using squalane as an O and distearoylphosphoethanolamine (DSPE) as an 
emulsifier engineered the TLR3a poly(I:C)-entrapping cationic nanoemulsions with a size 
of 200 nm and demonstrated that when given to mice the cationic nanoemulsions drained 
rapidly to the LNs and activated cross-presenting DCs, MPs as well as B cells, resulting in 
strong Ag-specific CD8+ T-cell responses [35]. The results suggest the squalane-based cationic 
nanoemulsions may be a promising VADS with the ability to induce strong CTL responses, 
offering an alternative way to make vaccines against pathogens that can hardly be protected 
without activated CTLs. Interestingly, using squalene as O but the 100 nm-sized poly(D, 
L-lactic-co-glycolide) (PLGA) NPs as a stabilizer, Ma and coworkers formulated 2 μm-sized 
Pickering emulsions as a VADS, which retained the force-dependent deformability and lat-
eral mobility of loaded Ags [36]. Mouse experiments proved that the Pickering emulsions 
enhanced the recruitment, Ag uptake, and activation of APCs which initiated robust humoral 
as well as cellular immunoresponses, which effectively supported mice to survive a lethal 
challenge of influenza virus. The outcomes hint that the pliability of vaccine carriers and 
lateral mobility of Ags may well count in triggering immune reactions and, as such, may well 
be taken into account when developing certain types of VADS.
In summary, as one of a few types of VADSs that have been approved for human use, certain 
types of emulsions prove by numerous clinical and preclinical evaluations capable of elic-
iting strong humoral and/or cellular immunity against heterologous pathogens meanwhile 
maintain an excellent safety profile, depending on the components as well as the structural 
characteristics of this fluid carrier. Further development of emulsion VADSs may focus on 
elucidating the mechanisms underlying the immunopotentiating functions in regard of par-
ticularly the relationship between emulsion efficacy, systematic characteristics, and molecular 
structure of squalene, squalane or other unidentified active materials [32]. Further efforts may 
well be committed to improving the stability of emulsions to construct a VADS allowing the 
products to be distributed, at least for some time, out of the cold chain [37], thus facilitating 
global vaccination against various infections in, especially, some low-income countries or 
districts, where integral cold chain may not be available.
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2.3. VADS constructed with liposomes formed by self-assembly of phospholipids
Liposomes are the phospholipid bilayer-enclosed vesicles and have attracted many research 
interests in the development of drug delivery system (DDS) as well as VADS ever since its dis-
covery by Bangham et al. in the early 1960s [38]. Liposomes usually consist of one or more con-
centric lipid bilayers alternating with aqueous spaces [39, 40], with the components of one, or 
more type of amphiphilic phospholipids such as phosphatidylcholine (PC), phosphatidylser-
ine (PS), phosphatidylglycerol (PG), and sphingomyelin (SM), which though form the frame 
structure of liposomes and are often supplemented with ingredients, such as cholesterol (CHO) 
and other charged lipids such as stearylamine (SA), N[1-(2,3-dioleyloxy) propyl]-N,N,N-
triethylammonium (DOTMA), 1,2-dioleyloxy-3-(trimethylammonium propane) (DOTAP), 
and 3 (N,N,-dimethylaminoethane)-carbamyl cholesterol (DMACHO), which are purposely 
used for tailoring the property of liposomes. Depending on ambient temperature and the 
nature of the lipids, the liposome bilayers may exist in either a “fluid” state when the ambient 
temperature is above the Tc (a gel to liquid crystalline transition temperature―the tempera-
ture at which the acyl chains melt) of liposomes, or a “rigid” state when the ambient tempera-
ture falls below the Tc of liposomes [40]. However, when CHO is homogenously incorporated 
into phospholipid bilayers, for example, at the mole ratio of CHO/PC between 1/3 and 2/3, 
the membrane rigidity may be significantly strengthened, and as a consequence, liposomes 
are blurred of Tc lowering content leakage. Bearing a common weakness of instability associ-
ated with a colloidal system, liposomes are often superficially PEGylated (modification with 
polyethylene glycol, PEG) to engender a steric stabilization effect, and/or are charged with an 
appropriate zeta potential value by the incorporated ionic lipids to generate an electrostatic 
repulsion for preventing aggregation, or for flocculating particles according to DLVO theory. 
Also, lyophilization is often employed to engender liposomes into a dry entity, which has a 
high stability completely satisfying the shelf-life requirements for clinical application, as it 
can be rehydrated to reconstitute the initial vesicles with little cargo leakage just in the pres-
ence of disaccharide as an effective lyoprotectant [41].
Liposomes possess numerous distinct properties enabling them to fulfill the functions of an 
excellent VADS, which can be summarized as aspects including good biocompatibility, high 
loading capacity for various ingredients, and the ease for preparation and surface decoration 
to engender specific functions such as targeting delivery, lysosome escape and controlled 
release [42]. With ability to entrap hydrophilic, lipophilic as well as amphiphilic molecules 
in the inner aqueous phase or lipid bilayers, liposomes have been formulated for deliver-
ing a large range of therapeutic agents, including small molecules, DNA/RNA fragments, 
peptides, and even proteins with a large molecular weight (MW), which exhibit respective 
therapeutic activities [39]. Also, liposomes are frequently employed as a VADS fitting diverse 
immunization routes, including intravenous, intramuscular, subcutaneous, intranasal, oral 
uptake, pulmonary inhalation, and topical skin or mucosal administration, for delivering 
vaccines to resolve problems associated with free Ags, for instances, averting premature inac-
tivation caused by environmental chemicals, and ensuring Ags to approach APCs and even 
the intracellular organelles without off-targets [43]. In particular, beneficial for acting as a 
VADS, liposomes possess the intrinsic adjuvant properties as established by Gregoriadis and 
coworkers in as early as 1974 when strong humoral immune responses to liposome-entrapped 
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diphtheria toxoid were observed after injection of the liposome vaccines into mice [40, 44, 45]. 
It is generally accepted that liposomes as a VADS function with the adjuvanticity regardless 
of the carrying mode of Ags, including entrapment within vesicles, attachment on surfaces, or 
simply mixing together [46, 47], which allows diverse modifications to be carried out on lipo-
somes without concerning the Ag damage through measures, including PEGylation, decora-
tion with PAMP molecules or the pattern recognition receptor agonists (PRRas), such as lipid 
A for TLR4, CpG-ODN for TLR9, and synthetic mannose derivatives for C-type receptors on 
APCs [8, 9, 37, 48, 49].
Notably, multifunctional liposomes have also been developed in combination with novel 
administration devices to form a VADS which can be employed to enhance immunization 
efficacy via convenient administration [47]. In particular, Wang’s group developed the mul-
tifunctional liposome-based VADSs through fabrication of liposomes adorned with TLR4a 
lipid A and loaded with Ags into biodegradable microneedle arrays, which can efficiently 
exert penetration of mucosa enhancing topical delivery efficiency [37, 48, 50]. Going further, 
Wang and coworkers engineered two types of multifunctional liposomes, the 200 nm-sized 
mannosylated lipid A-liposomes (MLLs) and the 50 nm stealth lipid A-liposomes (SLLs), both 
of which were loaded with Ags and NH
4
HCO
3
 and then packed together into microneedles, 
forming the proSLL/MLL-constituted microneedle array (proSMMA), which proved able to 
rapidly recover the initial MLLs and SLLs upon rehydration by tissue fluids [47]. Mice vac-
cinated with proSMMAs by vaginal mucosa patching established robust Ag-specific humoral 
and cellular immunity at both systemic and mucosal systems, especially, in the reproductive 
and intestinal ducts, owing to the action processes involving the facts that the MLLs reconsti-
tuted from the administered proSMMAs were mostly taken up by vaccination site-resident 
DCs for mucosal responses, whereas the smaller SLLs traveled to the dLDs wherein picked up 
by macrophages for efficient use of Ags. Furthermore, the delivered Ags were displayed by 
APCs via cross-presented with MHC-I thanks to lysosome escape and ROS (reactive oxygen 
species) stimulation, which were caused, respectively, by expansion of CO
2
 gas and induc-
tion of excessive NH
4
+/NH
3
 both sourcing from the liposome-released NH
4
HCO
3
, leading to a 
mixed Th1/Th2 type response promoted further by liposomal lipid A and activation of TLR4. 
Thus, though the large-scale production of the proSMMAs seems still a problem owing to the 
complex procedure for products and the instable entrapment of volatile NH
4
HCO
3
 in vesicles, 
the multifunctional VADS constructed with liposomal microneedles for vaginal immuniza-
tion provides an alternative strategy to elicit immunity against various pathogens, especially, 
the sexually transmitted ones. Moon et al. fabricated a novel VADS based on a special type 
of liposomes, which were called interbilayer-crosslinked multilamellar vesicles (ICMVs) and 
formed by crosslinking headgroups of adjacent phospholipid bilayers within multilamellar 
vesicles [51]. Further investigation showed that the stable Ag/adjuvant-carried ICMVs rap-
idly released the loaded cargos in response to catalysis by endolysosomal lipases, and when 
given to mice elicited robust endogenous T-cell and antibody responses, suggesting ICMVs a 
stimulus-sensitive VADS which may open up new possibilities for vaccination against infec-
tious diseases and cancer.
Summarily, liposomes are the most diverse carrier for delivering various agents and can be 
employed through diverse modifications with various functional molecules to constitute 
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different types of multifunctional VADS satisfying different vaccination requirements. As a 
proved by numerous experiments, at least in animal models, these multifunctional liposome 
VADSs are highly effective in both targeting delivery of vaccine to APCs and enhancing Ag 
presentation by APCs to related T-cells to set up the Ag-specific immunity against pathogens, 
fulfilling a dual function of adjuvancy and delivery for vaccines [7, 37, 47–49].
2.4. VADS constructed with ISCOMs formed by self-assembly of saponin and lipids
The immune stimulating complexes, named ISCOMs, are a type cage-like NPs with a size 
of 40 nm constructed of linked nanoring subunits with a size of 12 nm, and usually formed 
through self-assembly of the main components of phospholipids, cholesterol and, impor-
tantly, saponin which, as a crude mixture of numerous triterpene derivatives extracted from 
the cortex of the South-American Tree Quillaja saponaria Molina, has potent adjuvant activities 
[52]. ISCOM was first coined the name in 1984 by Morein et al. [53], who demonstrated that 
ISCOMs contained saponin Quil A, a heterogeneous mixture containing up to 23 different 
saponin compounds [54], and virus membrane proteins were at least 10 times more potent 
than micelles formed by aggregation of the protein Ags alone, but caused no severe side 
effects, such as hemolysis, associated with saponin. The strong immunostimulatory effects 
were argued to be resulted from large exposure of protein Ags in ISCOMs and the intrinsic 
adjuvanticity of saponin Quil A, while no severe adverse effects of hemolysis associated with 
saponin were noticed thanks to its tight association with cholesterol.
Being explored for high potency and low toxicity, Quil A was purified using reversed phase 
high performance liquid chromatography (RP–HPLC), by which Kensil et al. identified adju-
vant activity in 10 of the fractions including the four most abundant compounds, termed 
QS-7, 17, 18, and 21, with the numbers corresponding to their relative elution time, which 
is dependent on their degree of hydrophobicity using C4 resin column with RP–HPLC 
[55]. Similarly, Rönnberg et al. isolated three different RP–HPLC fractions of Quil A: QH-A 
sequences eluted early, further two sequences of the more hydrophobic fractions QH-B and 
QH-C, which were examined by pre-clinical toxicology and animal testing, resulting in an 
optimized combination of 7 parts QH-A, 0 parts QH-B and 3 parts QH-C, known as QH-703 
or ISCOPREP™703 (Iscotec AB, Sweden) [56], which was further developed into proprietary 
product ISCOPREP™ saponin by omitting QH-A fraction [57].
The identification of purified adjuvants from crude saponin allows ISCOMs to be formulated 
with more defined ingredients, such as monomer of QS21, ISCOPREP™ 703, and ISCOPREP™ 
[54], to constitute a VADS which can induce robust immunoresponses with Ags whether incor-
porated in the carrier or just physically mixed with the carrier [58, 59]. Formulation requiring 
no Ag incorporation not only simplifies the process of preparing the ISCOM vaccines but 
also expands the delivered Ags to include the hydrophilic ones; and the findings further sup-
ports the hypothesis that encapsulation of Ags in a carrier is not necessarily the prerequisite 
requirements for stimulating immunoresponses [60]. Duewell et al. developed the palmitified 
OVA-incorporated ISCOMs consisting of ISCOPREP, PC and cholesterol and showed that 
subcutaneous injection of OVA-ISCOMs to mice resulted in a substantial influx and activation 
of immune effector cells in dLNs in control of the vaccinated site and promoted natural killer 
(NK) and NK T cells to produce IFN-γ. Also, facilitated by the efficient Ag cross-presentation 
CD8α+ DCs in dLNs, a high frequency of different tumor cell killing Ag-specific CTLs was 
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differentiated and proliferated from relevant precursors [61] through MyD88 (the myeloid 
differentiation primary response gene 88) adapter protein-expression pathway, as revealed 
by Wilson et al. [62]. Notably, ISCOMs were upgraded by Schiött and coworkers to the next 
generation VADS, denoted Posintro™, which were cationic NPs formulated with cholesterol, 
DC-cholesterol (3β-(N-(N′,N′-dimethylaminoethane)-carbamoyl) cholesterol hydrochloride), 
POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), Quil A and HBsAg in the weight 
ratio of 3:1:4:20:5, engendering a new HBV vaccine of Posintro™-HBsAg [63]. In the intrader-
mally (i.d.) immunized animal models of mice and guinea pigs, Posintro™-HBsAg induced 
the strong response with high titers of HBsAg-specific antibody and high levels of cytotoxic 
T lymphocyte (CTL), demonstrating that Posintro™-HBsAg is promising both for the protec-
tion against HBV infection and as a potential therapeutic vaccine.
Notably, to develop effective vaccines against the deadly Ebola virus (EBV), which causes a fatal 
hemorrhagic fever in humans with a mortality of around 50%, as evidenced by the 2014–2016 
West Africa Ebola epidemic which claimed 11,310 lives in 28,600 infection cases [64], Bengtsson 
et al. engineered the 2014 EBV Makona strain glycoprotein (EBV/Mak GP) trimer VLPs (virus-
like particles) with a size of 30–40 nm using the Sf9 (engineered Spodoptera frugiperda) insect 
cell-recombinant baculovirus expression system [65]. In mice, adjuvanted with the Matrix-M 
which consists of two populations of 40 nm ISCOMs: 85% Matrix-A of saponin QH-A fraction 
+15% Matrix-C of saponin QH-C, EBV/Mak GP VLPs induced a rapid onset of specific IgG and 
neutralizing antibodies, increased frequency of multifunctional CD4+ and CD8+ T cells as well 
as effector B cells. Noteworthy, the immunity established in the vaccinated mice conferred a 
100% protection against a lethal viral challenge, suggesting the Matrix-M adjuvanted EBV/Mak 
GP VLP NPs an effective VADS for developing subunit vaccines against the deadly Ebola infec-
tions. Similarly, the group using Sf9 insect cell platform engineered a recombinant trivalent NP 
influenza vaccine (tNIV), which when intramuscularly administered with Matrix-M to ferrets 
induced high levels of broadly neutralizing antibodies against A (H1N1) strain, B strain and, 
especially, a panel of all historic (2000–2017) A/H3N2 strains [66]. In particular, in a clinical 
trial involving 330 adults, the 60-μg dose of tNIV/50 μg Matrix-M induced significantly greater 
HA inhibition antibody responses against a panel of wild-type A (H3N2) strains than did the 
inactivated trivalent vaccine Fluzone [67], showing that Matrix-M/tNIV may be an efficient 
strategy for developing the effective universal influenza vaccines with additional advantage in 
avoidance of the mismatching Ags as occurred in conventional procedures.
Summarily, the nanosized cage-like ISCOMs constituted through self-assembly of a combina-
tion of saponin, phospholipid and cholesterol are a multifunctional VADS, which can deliver 
or adjuvant Ags and, in both cases, can enormously boost the efficacy of subunit vaccines. In 
particular, ISCOMs can be combined with other adjuvants such as TLRas to further improve 
the immunostimulatory effects for enhancing function of adjuvanted Ags, thus providing a 
diverse platform for making therapeutic as well as prophylactic vaccines against pathogens 
or malicious neoplasms.
3. Conclusions
The NP-based VADSs provide an efficient strategy for delivering and enhancing efficacy 
of subunit vaccines, which are weak immunogens but represent the current trends in the 
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development of vaccines against various pathogens including cancer. The NPs formed through 
self-assembly of small molecules, especially, those possessing intrinsic adjuvanticity, are an 
attractive and promising VADS due to their numerous advantages, such as acceptable safety 
profile, ease for preparation and modification with functional materials as well as control of 
size, and fitting different vaccination routes, which may confer the carried vaccines multiple 
functions capable of eliciting the Ag-specific humoral as well as cellular immunity at both 
systemic and mucosal levels providing a strong protection against pathogens. Encouragingly, 
some subunit vaccines developed with the VADSs that are based on small molecule-assem-
bled NPs have already been approved for clinical vaccination, and typical products include 
the virosome-based hepatitis A vaccine (Epaxal®) and influenza vaccine (Inflexal V®), MF59-
based influenza vaccine (Fluad®), AS04-based HPV (Cervarix®) and HBV (Fendrix®) vaccines, 
and AS01-based malaria vaccine (Mosquirix®). Hopefully, as many problems associated with 
NP VADSs, such as high cost for products, and undefined mechanisms underlying immune 
reactions and associated adverse effects, are finally settled, more NP VADS-based subunit 
vaccines will be pushed into markets for conquering human life-threatening diseases, such as 
HIV infection, MERS infection, and even intractable cancers.
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